We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
MSD has announced more Keytruda (pembrolizumab) results, this time for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL).
The FDA has approved Adcetris to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma in combination with chemotherapy…